<DOC>
	<DOCNO>NCT00187252</DOCNO>
	<brief_summary>The purpose study evaluate whether add AF Suppression™ cardiac resynchronization therapy ( CRT ) improve prognosis heart failure patient benefit cardiac resynchronization therapy .</brief_summary>
	<brief_title>Mascot Study : Management Atrial Fibrillation ( AF ) Suppression AF-Heart Failure ( HF ) COmorbidity Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<criteria>HF patient New York Heart Association ( NYHA ) III IV Spontaneous QRS ≥130 m and/or mechanical interventricular delay &gt; 50 m Left ventricular ejection fraction ( LVEF ) ≤ 35 % Left ventricular end diastolic diameter ( LVEDD ) ≥ 55 mm Optimized medical regimen Age &gt; 18 year Unstable angina acute myocardial infarction ( MI ) ( &lt; 3 month ) Coronary artery bypass grafting ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) &lt; 3 month Life expectancy &lt; 6 month Permanent AF Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Ventricular Dyssynchrony</keyword>
</DOC>